CAPABILITIES OF ENDOSCOPIC ORGAN PRESERVATION TREATMENT OF INVASIVE BLADDER CANCER PATIENTS AT THE STAGE Ò2àN0M0
https://doi.org/10.24060/2076-3093-2012-0-3-37-40
Abstract
The combination of the transurethral vaporization, transurethral resection of bladder cancer together with the combined chemotherapy was applied( patent application no. 2010127350/20 (038956) d.d. 5.07.10 “Bladder cancer treatment method”). The developed system of a pseudo-multifactorial analysis was used to study the treatment results. The study proves that the combination of the transurethral resection and transurethral vaporization lets decrease both the number of bladder cancer recurrences and the number of complications. The treatment of bladder cancer patients at the stage Т2аN0M0 with the application of the systemic polychemotherapy and doxorubicin adjuvant chemotherapy according to the schedule lets the recurrence free survival get 93.0%. The results of our research prove the competence of the endoscopic organ preservation treatment to be applied to treat invasive cancers.
References
1. Housset M., Dufour E., Maulard-Durtux C. // Concomitant 5-fluouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer // Proc Am Soc Clin Oncol. – 1997. Vol. 16. – P. 1139.
2. Rodel C., Grabenbauer G.G., Kuhn R. et al. // Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results // J Clin Oncol. – 2002. – Jul. – Vol. 20(14). – P. 3061–3071.
3. Shipley W.U., Kaufman D.S., Zietman A.L. et al. Selective bladder preservation by combined modality therapy for invasive bladder cancer // Eur J Cancer. – 1995. – Vol. 31. №5. – P. 239.
4. Shipley W.U., Kaufman D.S., Heney N.M. et al. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer // Eur Urol. – 1998. – Vol. 33. №4. – P.32–34.
5. Shipley W.U., Kaufman D.S., Zehr E. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer // Urology. – 2002. Vol. 5. P. 236-242.
6. Weiss C., Wolze C., Engehausen D.G. et al. // Radiochemotherapy after transurethral resection for highrisk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy // J Clin Oncol. – 2006. Vol. 5. P. 1041-1078.
7. Wittlinger M, Rodel C.M., Weiss C. et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia // Radiother Oncol. – 2009. – Vol. 93(2). – P. 358–635.
8. Zietman A.L., Grocela J., Zehr E. et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder // Urology. 2001. – Sep. – Vol. 58(3). – P. 380–385.
Review
For citations:
Zimichev A.A. CAPABILITIES OF ENDOSCOPIC ORGAN PRESERVATION TREATMENT OF INVASIVE BLADDER CANCER PATIENTS AT THE STAGE Ò2àN0M0. Creative surgery and oncology. 2012;(3):37-40. (In Russ.) https://doi.org/10.24060/2076-3093-2012-0-3-37-40
Views:
598
Email this article 